RE: AACR 17th - 22nd April17 Apr 2026 18:38
Avacta could maybe tell them a thing or two about this.
"Shall I book you in for your annual prophylactic Dr Diehn?"...
Saturday Plenary Session to explore the next frontier of research on minimal residual disease in solid tumors
"Saturday’s Discovery Science Plenary will kick off the plenary program of the AACR Annual Meeting 2026. This year’s first Plenary Session, titled “The Next Frontier in Minimal Residual Disease: Solid Tumors,” will focus on the latest research on the evolution of drug resistance, the role of cancer cell heterogeneity and plasticity, and novel strategies to detect and target residual disease.
"The plenary program continues tomorrow with the Opening Plenary and through Wednesday, when it will close with a recap of the meeting’s highlights.
Maximilian Diehn, MD, PhDMaximilian Diehn, MD, PhD
"The session, chaired by Maximilian Diehn, MD, PhD, of Stanford University, will take place Saturday, April 18 from 4:15 to 6:15 p.m. PT in Hall H on the ground level of the San Diego Convention Center.
"Minimal residual disease (MRD) refers to microscopic amounts of cancer cells that are left behind after treatment, are hard to detect, and can drive recurrence. “Until recently, personalization of treatment based on MRD was largely limited to hematologic malignancies,” said Diehn. “However, recent advances in MRD detection technologies, particularly circulating tumor DNA (ctDNA)-based assays, have made it possible to detect MRD across many solid tumor types.”
"Over the past few years, MRD testing has become clinically available for common cancers such as those arising in the colon, breast, and lung, and a growing number of patients are receiving these tests as part of surveillance monitoring. However, the optimal ways to use these tests to maximize clinical benefit remain unclear, Diehn emphasized. “Therefore, a deeper understanding of MRD biology, how it can inform treatment strategies, and the clinical studies needed to demonstrate utility is especially timely,” he added.
"Diehn explained that this session will span topics from basic biology, including why some cancer cells survive therapy and the vulnerabilities of these cells, to clinical applications, such as emerging trial results and strategies for using MRD to guide patient care. “Together, these discussions will highlight both the scientific foundations and the translational potential of MRD in oncology.”
"(continues...)"
https://www.aacrmeetingnews.org/saturday-plenary-session-to-explore-the-next-frontier-of-research-on-minimal-residual-disease-in-solid-tumors/
Sign In
Follow the stocks
